LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Gesloten

28.71 0.35

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

27.72

Max

Belangrijke statistieken
By Trading Economics
Inkomsten	43M 13M
Verkoop	29M 107M
EPS	0.25
Winstmarge	12.139
Werknemers	524
EBITDA	16M 8.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+115.3% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	18M 1.5B
Vorige openingsprijs	28.36
Vorige sluitingsprijs	28.71

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

27.895 / 30.16 Steun & Weerstand

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mei 2026, 22:27 UTC

Acquisities, Fusies, Overnames

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mei 2026, 22:12 UTC

Winsten

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mei 2026, 21:52 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs

14 mei 2026, 23:57 UTC

Acquisities, Fusies, Overnames

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mei 2026, 23:56 UTC

Marktinformatie

Gold Prices Rise on Strong Demand -- Market Talk

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mei 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mei 2026, 23:47 UTC

Winsten

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mei 2026, 23:47 UTC

Winsten

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mei 2026, 23:28 UTC

Marktinformatie

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mei 2026, 23:00 UTC

Marktinformatie

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 mei 2026, 22:35 UTC

Marktinformatie

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mei 2026, 22:11 UTC

Acquisities, Fusies, Overnames

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mei 2026, 22:06 UTC

Marktinformatie

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mei 2026, 22:00 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q EPS 18c >NU

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q Rev $4.97B >NU

14 mei 2026, 21:22 UTC

Acquisities, Fusies, Overnames

G-III Apparel: Transaction Expected to Be Dilutive During First 12 Mos After Closing, With Accretion Expected Thereafter >GIII

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

115.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.33 USD 115.3%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

27.895 / 30.16Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.